Key result
In a propensity score-matched analysis of patients with advanced HFrEF and diabetes, metformin treatment was associated with better event-free survival compared to other glucose-lowering therapies.
Why the study?
The role of metformin in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus is not firmly established.
Does metformin improve survival and quality of life in patients with advanced HFrEF and type 2 diabetes mellitus compared to other glucose-lowering agents?
Cohort (n=847)
No
Does metformin improve survival and quality of life in patients with advanced HFrEF and type 2 diabetes mellitus compared to other glucose-lowering agents?
Metformin use in patients with advanced HFrEF and diabetes is associated with improved survival and quality of life compared to other glucose-lowering agents.
Answers are grounded in this paper and cite their sources.
Metformin was associated with better survival in advanced HFrEF with diabetes; hypothesis-generating and requires randomized confirmation before practice change.
Background: The role of metformin (MET) in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus (DM) is not firmly established. We studied the impact of MET on metabolic profile, quality of life (QoL) and survival in these patients. Methods: A total of 847 stable patients with advanced HFrEF (57.4± 11.3 years, 67.7% NYHA III/IV, LVEF 23.6± 5.8%) underwent clinical and laboratory evaluation and were prospectively followed for a median of 1126 (IQRs 410; 1781) days for occurrence of death, urgent heart transplantation or mechanical circulatory support implantation. Results: A subgroup of 380 patients (44.9%) had DM, 87 of DM patients (22.9%) were treated with MET. Despite worse insulin sensitivity and more severe DM (higher BMI, HbA1c, worse insulin resistance), MET-treated patients exhibited lower BNP, higher eGFR, better LV and RV function, less mitral and tricuspid regurgitation, were using smaller doses of diuretics (all p< 0.05) and had better QoL (MLHFQ: 36 vs. 48 points, p= 0.002). Compared to diabetics treated with other glucose-lowering agents, MET-treated patients had better event-free survival even after adjustment for BNP, BMI and eGFR (p= 0.035). Propensity score-matched analysis with 17 covariates yielded 81 pairs of patients and showed a significantly better survival for MET-treated subgroup (p= 0.01).Conclusion: MET treatment in patients with advanced HFrEF and DM is associated with better quality of life and improved outcome, by mechanisms beyond the improvement of blood glucose control. MET should stay among frontline drugs for treatment of DM in patients with HFrEF.
No takes yet. Share an insight, caveat, or question.
Beneš et al. (2022) conducted a cohort in Advanced heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (n=847). Metformin vs. Other glucose-lowering agents (metformin-free) was evaluated on Combined endpoint of death, urgent heart transplantation, or mechanical circulatory support implantation (p=0.01). In a propensity score-matched analysis of patients with advanced HFrEF and diabetes, metformin treatment was associated with better event-free survival compared to other glucose-lowering therapies.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: